Xixiang Li

发表

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Qingsong Liu, Zhenquan Hu, Cheng Chen, 2021, European journal of pharmacology.

Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis.

Qingsong Liu, Zhenquan Hu, S. Cao, 2018, Journal of natural products.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Jing Liu, Cheng Chen, Wei Wang, 2017, Journal of medicinal chemistry.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Zhenquan Hu, Q. Liu, Hong Wu, 2017, Journal of medicinal chemistry.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

Qingsong Liu, Q. Liu, Hong Wu, 2022, Acta Pharmacologica Sinica.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Q. Liu, Zong-ru Jiang, Juan Liu, 2023, European journal of pharmacology.

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

Zhenquan Hu, Q. Liu, Hong Wu, 2019, Cancer biology & therapy.

Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair

Qingsong Liu, Hong Wu, Chu Wang, 2020, Chembiochem : a European journal of chemical biology.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.